TARPLIN, DOWNS & YOUNG, LLC for SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION)
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 18, 2014 | $60,000 | Replaced |
| 1st Quarter - Amendment (this page) | Jan 3, 2017 | $60,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Health care reform, drug importation, 340b, biosimilars PL 111-148 - The Patient Protection and Affordable Care Act, PL 111-152 - The Reconciliation Act of 2010, implementation PL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation H.R. 2186 - Valid Compounding Act H.R. 3204 - The Drug Quality and Security Act, implementation H.R. 2725, S. 1413 - Safety Over Sequester Act, user fee sequester relief H.R. 1281/S. 1417 - Newborn Screening Saves Lives Reauthorization Act ***no specific bills, importation, Prescription Drug User Fee Act Renewal and associated policies, supply chain integrity, user fee sequester
Foreign entity interest: "As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Form LD-1, has an interest in the issues lobbied."
| Lobbyist | Covered position, as disclosed |
|---|---|
| RAISSA H DOWNS | — |
| MICHELLE P EASTON | — |
| LINDA E TARPLIN | — |
| JENNIFER B YOUNG | — |
Medicare/Medicaid MMM
PL 111-148 - The Patient Protection and Affordable Care Act, implementation, ESRD, clinical laboratory payment H.R. 351/S. 351 - Protecting Seniors' Access to Medicare Act of 2013, IPAB H.R. 2810 - Medicare Patient Access and Quality Improvement Act of 2013, SGR S. 1871 - SGR Repeal and Medicare Beneficiary Access Act of 2013 H.R. 4302 - Protecting Access to Medicare Act of 2014 ***, no specific bill(s), implementation of QIP and MIPPA ESRD bundling provisions, Medicare Reimbursement, Medicaid Rebate, Medicaid reimbursement, quality indicators, deficit reduction
Foreign entity interest: "As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Form LD-1, has an interest in the issues lobbied."
| Lobbyist | Covered position, as disclosed |
|---|---|
| RAISSA H DOWNS | Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Staff Dir., Sub. Cmte. on Employment, Sen. HELP Cmte. |
| MICHELLE P EASTON | Chief Health Counsel, Sen. Cmte. On Finance; Staff Dir., Senate Aging Cmte.; Leg. Asst. Congressman Billy Tauzin |
| LINDA E TARPLIN | Sp. Asst. to the Pres. for Leg. Affairs; Dep. Asst. Sec. for Leg. - HHS |
| JENNIFER B YOUNG | Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff, Sen. Cmte. on Finance |
Budget/Appropriations BUD
budget resolution, reconciliation, deficit reduction, debt ceiling H.R. 3547, the Consolidated Appropriations Act, 2014
Foreign entity interest: "As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Form LD-1, has an interest in the issues lobbied."1
| Lobbyist | Covered position, as disclosed |
|---|---|
| RAISSA H DOWNS | — |
| MICHELLE P EASTON | — |
| LINDA E TARPLIN | — |
| JENNIFER B YOUNG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.